Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Hematology"
DOI: 10.1007/s12185-017-2319-9
Abstract: In this phase 2 study, patients with solid tumors receiving gemcitabine monotherapy or gemcitabine plus cisplatin/carboplatin were randomized 2:1 to eltrombopag 100 mg (n = 52) or placebo (n = 23) for 5 days before and after chemotherapy was started. The… read more here.
Keywords: chemotherapy; solid tumors; gemcitabine; tumors receiving ... See more keywords
Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: a retrospective cohort study.
Sign Up to like & getrecommendations! Published in 2022 at "Acta clinica Belgica"
DOI: 10.1080/17843286.2022.2153465
Abstract: OBJECTIVES Ferric carboxymaltose (FCM) is increasingly used in the management of cancer-related anemia, yet it may cause hypophosphatemia. This retrospective study describes the incidence, evolution and risk factors of hypophosphatemia in a cohort of patients… read more here.
Keywords: patients solid; hypophosphatemia; tumors receiving; risk factors ... See more keywords